The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature Full Text
European Urology, 08/04/2011
Sonpavde G et al. – Abiraterone acetate (AA) specifically inhibits CYP17 and substantially reduces serum androgen levels without inducing significant adrenal insufficiency. A phase 3 trial reported a significant extension of survival in metastatic castration–resistant prostate cancer (CRPC) with AA plus prednisone compared to prednisone alone following docetaxel. The primary toxicity of mineralocorticoid excess is manageable. The addition of low–dose corticosteroids to AA may be necessary for controlling symptoms of mineralocorticoid excess.